Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.02M | $-130.15M | $-2.05 |
| 2024 | $434.43M | $275.19M | $4.47 |
| 2023 | $60.00M | $-78.95M | $-1.39 |
| 2022 | $26.58M | $-127.39M | $-2.52 |
| 2021 | $27.36M | $-125.55M | $-2.65 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $2.19 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.29 vs $2.27beat
- Tue, May 5$0.05 vs $-0.65beat
- Wed, Feb 25$-0.69 vs $-0.53miss
- Thu, Nov 6$-0.62 vs $-0.59miss
- Wed, Aug 6$-0.55 vs $-0.53miss
- Tue, May 6$-0.19 vs $-0.50beat
Estimates and results for PTGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PTGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·3d ago·Positive
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis
View source ↗